2023
Transcatheter versus surgical aortic valve replacement in lower-risk and higher-risk patients: a meta-analysis of randomized trials
Ahmad Y, Howard J, Arnold A, Madhavan M, Cook C, Alu M, Mack M, Reardon M, Thourani V, Kapadia S, Thyregod H, Sondergaard L, Jørgensen T, Toff W, Van Mieghem N, Makkar R, Forrest J, Leon M. Transcatheter versus surgical aortic valve replacement in lower-risk and higher-risk patients: a meta-analysis of randomized trials. European Heart Journal 2023, 44: 836-852. PMID: 36660821, DOI: 10.1093/eurheartj/ehac642.Peer-Reviewed Original ResearchConceptsSurgical aortic valve replacementTranscatheter aortic valve implantationHigh-risk patientsLow-risk patientsComposite of deathAortic valve replacementValve replacementMAIN OUTCOMENew-onset atrial fibrillationSignificant differencesRandomized clinical trial dataAcute kidney injuryAortic valve implantationMain clinical outcomesRisk of deathClinical trial dataMajor bleedingKidney injurySecondary endpointsVascular complicationsValve implantationClinical outcomesParavalvular leakRandomized trialsAtrial fibrillation
2022
Catheter ablation improves cardiovascular outcomes in patients with atrial fibrillation and heart failure: a meta-analysis of randomized controlled trials
Simader FA, Howard JP, Ahmad Y, Saleh K, Naraen A, Samways JW, Mohal J, Reddy RK, Kaza N, Keene D, Shun-Shin MJ, Francis DP, Whinnett ZI, Arnold AD. Catheter ablation improves cardiovascular outcomes in patients with atrial fibrillation and heart failure: a meta-analysis of randomized controlled trials. EP Europace 2022, 25: 341-350. PMID: 36305545, PMCID: PMC9934993, DOI: 10.1093/europace/euac173.Peer-Reviewed Original ResearchConceptsHeart failure hospitalizationCatheter ablationHeart failureMedical therapyFailure hospitalizationAtrial fibrillationCardiovascular outcomesPrimary analysisPre-specified primary endpointAtrial fibrillation catheter ablationCause mortalityPrimary endpointSecondary endpointsLower riskPatientsTherapyHospitalizationFibrillationTrialsMortalityLow heterogeneityAblationEndpointOutcomesFailureLong-Term Outcomes of Randomized Controlled Trials Comparing Percutaneous Left Atrial Appendage Closure to Oral Anticoagulation for Nonvalvular Atrial Fibrillation: A Meta-Analysis
Madhavan M, Howard J, Brener M, Der Nigoghossian C, Chen S, Makkar R, Osmancik P, Reddy V, Holmes D, Stone G, Leon M, Ahmad Y. Long-Term Outcomes of Randomized Controlled Trials Comparing Percutaneous Left Atrial Appendage Closure to Oral Anticoagulation for Nonvalvular Atrial Fibrillation: A Meta-Analysis. Structural Heart 2022, 7: 100096. PMID: 37275318, PMCID: PMC10236864, DOI: 10.1016/j.shj.2022.100096.Peer-Reviewed Original ResearchLeft atrial appendage closurePercutaneous left atrial appendage closureRandomized clinical trialsNonvalvular atrial fibrillationOral anticoagulationAtrial appendage closureAtrial fibrillationNonprocedural bleedingCause mortalityAppendage closureHazard ratioHemorrhagic strokeClinical trialsLong-term oral anticoagulationReduced long-term riskLarge-scale clinical trialsIndividual clinical endpointsPrespecified primary endpointCochrane Central RegisterStandard of careNew trial dataSignificant differencesLong-term riskStroke prophylaxisPrimary endpoint
2018
2 PFO closure is superior to medical therapy for cryptogenic stroke: a meta-analysis of randomised controlled trials
Ahmad Y, Howard J, Arnold A, Shun-Shin M, Cook C, Malik I, Mayet J, Francis D, Sen S. 2 PFO closure is superior to medical therapy for cryptogenic stroke: a meta-analysis of randomised controlled trials. Heart 2018, 104: a2. DOI: 10.1136/heartjnl-2018-bcs.2.Peer-Reviewed Original ResearchMedical therapyCryptogenic strokeDevice closureAtrial fibrillationRecurrent strokePFO closureNew-onset atrial fibrillationRisk of AFOnset atrial fibrillationPrimary safety endpointPrimary efficacy endpointPrevention of strokeEfficacy endpointFurther strokeSafety endpointTreat basisPatent foramenPatientsTherapyStrokePFOTrialsEndpointPreventionClosurePatent foramen ovale closure vs. medical therapy for cryptogenic stroke: a meta-analysis of randomized controlled trials
Ahmad Y, Howard JP, Arnold A, Shin MS, Cook C, Petraco R, Demir O, Williams L, Iglesias JF, Sutaria N, Malik I, Davies J, Mayet J, Francis D, Sen S. Patent foramen ovale closure vs. medical therapy for cryptogenic stroke: a meta-analysis of randomized controlled trials. European Heart Journal 2018, 39: 1638-1649. PMID: 29590333, PMCID: PMC5946888, DOI: 10.1093/eurheartj/ehy121.Peer-Reviewed Original ResearchConceptsMedical therapyCryptogenic strokeDevice closurePFO closureAtrial fibrillationRecurrent strokeLarge shuntPatent foramenNew-onset atrial fibrillationRisk of AFOnset atrial fibrillationPrimary safety endpointPrimary efficacy endpointAtrial septal aneurysmPrevention of strokeSignificant reductionEfficacy endpointFurther strokeSafety endpointTreat basisSeptal aneurysmSmall shuntPatientsTherapyStroke
2013
Is bleeding a necessary evil? The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation
Myat A, Ahmad Y, Haldar S, Tantry US, Redwood SR, Gurbel PA, Lip GY. Is bleeding a necessary evil? The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation. Expert Review Of Cardiovascular Therapy 2013, 11: 1029-1049. PMID: 23984927, DOI: 10.1586/14779072.2013.815423.Peer-Reviewed Original ResearchConceptsStroke preventionAntithrombotic therapyAntithrombotic agentsNovel oral anticoagulation agentsAtrial fibrillation guidelinesOral anticoagulation agentsDrug-drug interactionsDirect antidoteAF patientsAnticoagulation monitoringAnticoagulation agentsAtrial fibrillationAbsolute riskAntithrombotic pharmacotherapyRelative riskLower riskStrong recommendationsPatientsThromboembolismPreventionRiskTherapyInherent risksAuthors' knowledgeAgentsRecent Developments in Understanding Epidemiology and Risk Determinants of Atrial Fibrillation as a Cause of Stroke
Ahmad Y, Lip GY, Lane DA. Recent Developments in Understanding Epidemiology and Risk Determinants of Atrial Fibrillation as a Cause of Stroke. Canadian Journal Of Cardiology 2013, 29: s4-s13. PMID: 23790597, DOI: 10.1016/j.cjca.2013.03.009.Peer-Reviewed Original ResearchConceptsDevelopment of AFAtrial fibrillationRisk factorsStroke riskAF patientsOccurrence of AFEffective oral anticoagulationAcute cardiac conditionsCause of strokeLow-risk patientsNovel risk factorsNovel therapeutic targetPublic health consequencesFormal anticoagulationOral anticoagulationRisk patientsPatient cohortCardiac conditionsEpidemic proportionsTherapeutic targetClinical practicePatientsAnticoagulationHealth consequencesRisk determinantsPreventing Stroke and Systemic Embolism in Renal Patients with Atrial Fibrillation: Focus on Anticoagulation
Ahmad Y, Lip GY. Preventing Stroke and Systemic Embolism in Renal Patients with Atrial Fibrillation: Focus on Anticoagulation. Contributions To Nephrology 2013, 179: 81-91. PMID: 23652451, DOI: 10.1159/000346726.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnticoagulantsAtrial FibrillationBenzimidazolesBeta-AlanineClinical Trials as TopicComorbidityDabigatranDisease ManagementEmbolismFemaleFibrinolytic AgentsHemorrhageHumansHypertensionIntracranial EmbolismMaleMorpholinesPatient SelectionPyrazolesPyridonesRenal Insufficiency, ChronicRiskRisk FactorsRivaroxabanSeverity of Illness IndexStrokeThiophenesThrombophiliaWarfarinConceptsSevere renal impairmentAtrial fibrillationRisk factorsGeneral populationRenal impairmentRenal diseaseRenal patientsAbsence of AFLarge randomised control trialBenefits of warfarinNew oral anticoagulantsChronic kidney diseaseCohort of patientsRisk of strokeRandomised control trialEctopic vascular calcificationMajority of trialsUnique management challengesAF independentSystemic embolismOral anticoagulantsRenal insufficiencyStroke preventionThromboembolic riskStroke risk
2012
New oral anticoagulants for stroke prevention in atrial fibrillation: impact of gender, heart failure, diabetes mellitus and paroxysmal atrial fibrillation
Ahmad Y, Lip GY, Apostolakis S. New oral anticoagulants for stroke prevention in atrial fibrillation: impact of gender, heart failure, diabetes mellitus and paroxysmal atrial fibrillation. Expert Review Of Cardiovascular Therapy 2012, 10: 1471-1480. PMID: 23253272, DOI: 10.1586/erc.12.148.Peer-Reviewed Original ResearchConceptsNew oral anticoagulantsParoxysmal atrial fibrillationOral anticoagulantsNonparoxysmal atrial fibrillationAtrial fibrillationHeart failureStroke preventionNew anticoagulantsContemporary phase III trialsAdditional prognostic benefitPhase III trialsPresence of diabetesNew drugsImpact of genderIII trialsPrognostic benefitDiabetes mellitusAnticoagulantsPatientsWarfarinEvent ratesCardiovascular medicineFibrillationMellitusDiabetesStroke Prevention in Atrial Fibrillation: Concepts and Controversies
Ahmad Y, Lip G. Stroke Prevention in Atrial Fibrillation: Concepts and Controversies. Current Cardiology Reviews 2012, 8: 290-301. PMID: 22920480, PMCID: PMC3492813, DOI: 10.2174/157340312803760820.Peer-Reviewed Original ResearchConceptsStroke risk factorsAtrial fibrillationOral anticoagulationStroke preventionRisk factorsPatient riskIndependent stroke risk factorNew oral anticoagulantsCommon cardiac rhythm disorderLow-risk patientsCardiac rhythm disordersAntiplatelet therapyAntithrombotic therapyOral anticoagulantsSevere strokePerioperative managementEffective therapyRhythm disordersEfficacious agentsGeneral populationNew agentsSimple scorePatientsAnticoagulationFibrillationDabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: NICE guidance
Ahmad Y, Lip GY. Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: NICE guidance. Heart 2012, 98: 1404. PMID: 22698856, DOI: 10.1136/heartjnl-2012-302101.Peer-Reviewed Original ResearchConceptsPrevention of strokeSystemic embolismAtrial fibrillationNICE guidanceEmbolismFibrillationStrokePreventionStroke Prevention in Atrial Fibrillation: Where are We Now?
Ahmad Y, Lip GY. Stroke Prevention in Atrial Fibrillation: Where are We Now? Clinical Medicine Insights Cardiology 2012, 6: cmc.s8976. PMID: 22408371, PMCID: PMC3296491, DOI: 10.4137/cmc.s8976.Peer-Reviewed Original ResearchStroke preventionAtrial fibrillationOnly successful therapyLow-risk patientsBetter risk stratificationStroke prophylaxisRisk stratificationCommon arrhythmiaNovel anticoagulantsSuccessful therapyWarfarinPatientsGreater mortalityPreventionFibrillationAF researchEffective alternativeNew optionsAnticoagulationImproved management strategiesProphylaxisAnticoagulantsArrhythmiasTherapyMajor progressAnticoagulation in Atrial Fibrillation.
Ahmad Y, Lip GY. Anticoagulation in Atrial Fibrillation. Arrhythmia & Electrophysiology Review 2012, 1: 12-16. PMID: 26835023, PMCID: PMC4711491, DOI: 10.15420/aer.2012.1.12.Peer-Reviewed Original ResearchAtrial fibrillationMost thromboembolic complicationsEfficacy of warfarinNew oral anticoagulantsRisk stratification schemesOral anticoagulationAntithrombotic therapyOral anticoagulantsSevere strokeThromboembolic riskThromboembolic complicationsAF patientsAnticoagulant monitoringCommon arrhythmiaNew anticoagulantsWorse outcomesImproved outcomesNew agentsPatientsAF treatmentStratification schemesAnticoagulationDose variabilityAnticoagulantsWarfarin